Founded in 1997, ChemoCentryx is a clinical-based pharmaceutical company that discovers and develops orally-administered small molecule therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. It has developed EnabaLink, which is a drug recovery technology that is designed to accelerate productive drug recovery program. The company also conducts preclinical evaluation of a series of anticancer compounds that target the CXCR7 chemokine receptor. ChemoCentryx evaluates a series of compounds that target the C5a chemo-attractant receptor to treat age-related macular degeneration, rheumatoid arthritis and systemic lupus erythematosus and other disorders. It has entered into a strategic alliance with Glaxo Group, which is an affiliate of GlaxoSmithKline. ChemoCentryx maintains its headquarters in Mountain View, Calif.